WellCare, Centene reportedly interested in Aetna’s Medicare Advantage business

| | Health Exec | Economics

Aetna is looking to jettison its Medicare Advantage plans in order to placate antitrust concerns at the Department of Justice over its proposed merger with Humana, and Reuters is reporting at least two companies are competing for that portfolio.

Sources “familiar with the matter” say WellCare and Centene have submitted for bids for plans that cover around 350,000 patients, with a possible sale price of $1 billion.

To read more on the potential sale and how it may affect regulators’ final decision on the Aetna-Humana deal, click on the link below: 

Exclusive: WellCare, Centene make offers for Aetna assets - sources

Related Content

American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward
UnitedHealth pushes back against shareholder transparency proposal
Thousands of staff cut from federal health agencies, including CDC and VA
Nonprofit academic hospital receives criticism after running Super Bowl ad
HeartBeam raising $10M for FDA-cleared health tech with public offering

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”